- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions

European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
Pharmaceuticals - Community Register
Community list of not active medicinal products for human use |
WITHDRAWN |
Product information |
Invented name: | Sepioglin |
Auth. number : | EU/1/12/754 |
Active substance : | pioglitazone |
ATC: | Anatomical main group: A - Alimentary tract and metabolism Therapeutic subgroup: A10 - Drugs used in diabetes Pharmacological subgroup: A10B - Blood glucose lowering drugs, excluding insulins Chemical subgroup: A10BG - Thiazolidinediones Chemical substance: A10BG03 - pioglitazone (See WHO ATC Index) |
Indication: | Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy
|
Marketing Authorisation Holder: | Vaia S.A.
1, 28 Octovriou str., Ag. Varvara 123 51, Athens, Ελλάδα |
EPAR and active package presentations![]() | |
Package presentations |
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information". Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register. |
European Commission procedures |
Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
12/03/2012 | Centralised - Authorisation - Decision addressed to Member States | EMEA/H/C/2021 | (2012)1734 of 09/03/2012 | |||
13/03/2012 | Centralised - Authorisation | EMEA/H/C/2021 | (2012)1733 of 09/03/2012 | |||
10/06/2013 | Centralised - Withdrawal | (2013)3517 of 06/06/2013 |